

OVERCOMING THE FEAR OF WOUND INFECTION

**THURSDAY
29 JULY
7.30 - 8.30**

FACEBOOK LIVE

Journal of Community Nursing



**LUXMI DHOONMOON
NURSE CONSULTANT
TISSUE VIABILITY**



SPONSORED BY:  **Flen Health**

OBJECTIVES

To:

- Identify infection in the wound bed
- Differentiate between stages of colonisation/infection
- Understand the importance of managing infection effectively
- Discuss the use of an enzyme alginogel as an antimicrobial

WOUND INFECTION — FACTS



- Painful for the patient
- Leads to increased morbidity
- Cause of mortality
- Frequent risk of hospitalisation
- Increasing risk to society — antimicrobial resistance
- Clinical management problem

SIGNS AND SYMPTOMS OF INFECTION

Textbook criteria of signs of infection...

Pain

Erythema

Abscess

Delayed healing/
Wound breakdown

Confusion

Changes in granulation
tissue


Cellulitis

Induration or oedema
at wound edges

Malodour

Exudate —
colour/texture/volume

INTERNATIONAL CONSENSUS DOCUMENT




The most up to-date IWII consensus document 'Wound Infection in Clinical Practice'. Authored by leading experts in wound management:

Authors

Terry Swanson, South West Healthcare, Warrnambool, Victoria (Australia)
Donna Angel, Royal Perth Hospital, Perth (Australia)
Geoff Sussman, Monash University, Melbourne (Australia)
Rose Cooper, Cardiff Metropolitan University, Cardiff (UK)
Emily Haesler, Curtin University and Australian National University, Canberra (Australia)
Karen Ousey, Institute of Skin Integrity and Infection Prevention, Huddersfield (UK)
Keryn Carville, Silver Chain Group and Curtin University, Perth (Australia)
Jacqui Fletcher, Independent Nurse Consultant (UK)
Lindsay Kalan, University of Pennsylvania, Philadelphia, Pennsylvania (USA)
David Keast, Lawson Health Research Institute, London, Ontario (Canada)
David Leaper, Imperial College, London (UK)
Greg Schultz, University of Florida, Gainesville, Florida (USA)
Joyce Black, University of Nebraska Medical Center Omaha, Nebraska (USA)
Evan Call, EC Service and Weber State University, Centerville, Utah (USA)

STAGES IN THE WOUND INFECTION CONTINUUM



Ref: <https://woundinfection-institute.com/wp-content/uploads/2019/07/evolution-wound-infection-continuum.pdf>

COLONISATION



- All chronic wounds are colonised (leg ulcers, pressure ulcers and diabetic foot ulcers) up to the point of healing
- Do NOT over treat with antimicrobials

LOCAL INFECTION



- Wounds will not heal despite 'standard care'
- It is painful
- Strikethrough
- Local infection is contained in one location, system or structure

SPREADING INFECTION



- The invasion of the surrounding tissue by infective organisms that have spread from a wound
- Microorganisms proliferate and spread to a degree that signs and symptoms extend beyond the wound border

SYSTEMIC INFECTION

- It affects the body as a whole, with microorganisms spreading throughout the body via the vascular or lymphatic systems
- Systemic inflammatory response, sepsis and organ dysfunction are signs of systemic infection

OVERCOMING WOUND INFECTION

Once assessed and identified as being infected, a wound can be treated using the following methods:

Systemic antibiotics	These should be reserved for appropriate use
Topical antimicrobial agents	Useful in managing bioburden
Non-medicated dressings	Useful alternative to manage wound bioburden

Examples of antimicrobials listed are the presenter's preferred selection based on local formulary: iodine, silver, honey, polyhexamethylene biguanide (PHMB) and enzyme alginogel

WHAT KIND OF WOUNDS DO WE SEE?

Moisture lesions

Skin tears

Surgical wounds

Fungating wounds

Adult/child wounds

Trauma wounds

Pressure ulcers

Leg ulcers

Diabetic foot ulcers

Burns (inc. radiotherapy
burns)

MANAGING INFECTION USING ANTIMICROBIALS

INTERNATIONAL CONSENSUS UPDATE 2016



WOUND INFECTION IN CLINICAL PRACTICE

Principles of best practice

Table 7: Topical wound infection therapies			
Antimicrobial agent	Type	Biofilm efficacy	Guidance for use
Enzyme alginate gel	Alginate gel with two enzymes: <ul style="list-style-type: none"> Lactoperoxidase Glucose oxidase 	<ul style="list-style-type: none"> Prevents formation of biofilms at concentration MO.5% (w/v)^{112,113} Inhibits growth of established biofilms at higher concentrations Does not disrupt biofilm biomass^{112,113} 	<ul style="list-style-type: none"> Concentrations of alginate of 3% and 5% depending on level of exudate^{112,113}
Iodine (povidone and cadexomer)	<ul style="list-style-type: none"> Solution Impregnated wound dressings Powder and paste 	<ul style="list-style-type: none"> Inhibits development of new biofilm^{110, 114} Eradicates young biofilm colonies^{110, 115} Significantly reduces mature biofilm colonies^{110, 114} 	<ul style="list-style-type: none"> Contraindicated in individuals sensitive to iodine or with thyroid or renal disorders¹¹⁰ Contraindicated in those with extensive burns¹¹⁰
Honey	<ul style="list-style-type: none"> Medical grade Honey impregnated dressings 	<ul style="list-style-type: none"> Inhibits biofilm growth¹¹⁶⁻¹¹⁸ Reduces biofilm colony formation¹¹⁹ Inhibits quorum sensing of biofilm, thereby reducing ability to proliferate¹²⁰ 	<ul style="list-style-type: none"> Select products that have been gamma irradiated¹¹⁹ Leptospermum species is more effective than other types¹¹⁹
Silver	<ul style="list-style-type: none"> Salts (e.g. silver sulphadiazine, silver nitrate, silver, sulphate, silver CMC) Metallic, e.g. nanocrystalline, silver-coated nylon fibres Impregnated wound dressings 	<ul style="list-style-type: none"> Denatures existing bacterial biofilm in concentrations over 5 µg/ml¹²⁰ 	<ul style="list-style-type: none"> Change more frequently in wounds with heavy exudate Avoid in individuals with silver sensitivities¹²¹
Ionic silver combined ethylenediamine-tetraacetate (EDTA) and benzethonium chloride (BEC) (antibiofilm agents)	<ul style="list-style-type: none"> Carboxymethylcellulose gelling dressing impregnated with ionic silver enhanced with EDTA and BEC 	<ul style="list-style-type: none"> Combines antibiofilm and antimicrobial components that work in synergy to disrupt biofilm and expose associated microorganisms to the broad-spectrum antimicrobial action of ionic silver¹²² Eradicates mature biofilm within 5 days¹²⁴ Prevents biofilm formation¹²⁴ Associated improvement in healing rates¹²⁵ 	<ul style="list-style-type: none"> Change more frequently in wounds with heavy exudate Avoid in individuals with sensitivities to silver, EDTA or BEC¹²³
Surfactant	<ul style="list-style-type: none"> Concentrated surfactant gels with antimicrobial preservatives 	<ul style="list-style-type: none"> Prevents biofilm formation¹²⁶ Increases antibiotic efficacy Eradicates mature biofilm 	<ul style="list-style-type: none"> Can be used between and post-debridement to prevent re-establishment of biofilm May require daily application for the first few days

WHAT IS FLAMINAL®

Flaminal® consists of three essential components for wound healing

1

Debriding gel

The gel dissolves necrotic tissue and fibrin and absorbs them from the wound bed

2

Absorbent alginate

It contains an absorbent alginate that helps with the absorption of debris, bacteria and excess exudate

3

Antimicrobial enzyme system

It contains an antimicrobial enzyme system that protects the wound against microbial colonisation and infection


WOUND BED PREPARATION... THE FACTS

Flaminal[®] can be used in all five aspects of the T.I.M.E.S. paradigm

Tissue	Continuous autolytic debridement
Infection	Antimicrobial protection
Moisture	Moist wound healing and absorbs exudate
Edge of wound	Safe for skin and skin tissue and protects wound edges
Surrounding skin	Does not damage surrounding skin

CASE STUDIES

CASE STUDY ONE — PRESSURE ULCER



Patient:

- 50-year-old female, still in employment
- Multiple sclerosis, wheelchair bound

Wound:

- TVN initial assessment in community: category 4 pressure ulcer to left buttock
- High volume of exudate, malodour, no pain
- Combination of slough and unhealthy granulation in base and bone palpable
- Surrounding skin unaffected but fragile

Treatment aim:

- Reduce slough and bioburden
- Manage exudate effectively
- Improve patient's quality of life (QOL)
- Enzyme alginogel started to reduce slough and manage exudate

CASE STUDY ONE — PRESSURE ULCER

4 weeks later



Few months later



CASE STUDY TWO — FUNGATING WOUND



Patient:

- 93-year-old female
- Atrial fibrillation
- Hypothyroidism
- Hypertension
- Squamous cell carcinoma (SCC) spreading to left side of face

Wound:

- SCC wound — fungating to left side of face
- High volume of thick exudate
- Malodorous
- Surrounding skin affected and friable — bleeds on contact
- Several bleeds as scab gets caught in dressing

Treatment aim:

- Reduce exudate and malodour
- Manage friable areas more effectively
- Improve patient's QoL
- Enzyme alginogel started

CASE STUDY TWO — FUNGATING WOUND

Self-care

- Covid pandemic period
- Not keen for nurses to attend regularly
- Works with grandson who wanted to do something for patient
- Teach him how to do simple wound care
- Gentle cleaning with antimicrobial wash mitt — no rubbing
- Apply Flaminal® Forte daily to all affected areas
- No secondary dressing was required

After 2 weeks

- Scabs gently coming off — no bleeding
- Malodour reduced
- Minimal exudate leaking on face
- Able to eat better, as no malodour

After 4 weeks

- Eye was cleared and slightly opened
- Both grandson and patient were in tears
- No exudate at all

CASE STUDY THREE — EXTREME MASD



Patient:

- 87-year-old female
- Type 2 diabetes
- Hypertension, disc fusion
- Reduced mobility, recurrent falls, needs two people to transfer using equipment

Wound:

- Moisture-associated skin damage (MASD)
- Bleeding due to friable skin
- Incontinent of both urine and faeces
- Barrier cream used, carers educated on appropriate skin care regimen
- Rapid deterioration after episode of loose stool
- Surrounding skin affected and fragile

Treatment aim:

- Improve skin integrity and ease of application for carers due to incontinence
- Improve patient's QoL, ability to sit out for meal times
- Enzyme alginogel started

CASE STUDY THREE

4 weeks later



8 weeks later



CASE STUDY THREE



- Antifungal properties
- Acts as a protective barrier
- Non-cytotoxic: hence can be left on healthy skin without causing maceration

CASE STUDY FOUR — DIABETIC FOOT ULCER

Dec 2012



Patient:

- 64-year-old male
- Type 2 diabetes for over 15 years
- Ischaemic heart disease, nephropathy, retinopathy and peripheral vascular disease

Wound:

- DFU following a neuro-ischaemic amputation of left forefoot
- High volume of exudate
- Deep sloughy wound which encompassed the whole of his forefoot to the bone
- Surrounding skin unaffected

Treatment aim:

- Reduce slough and bioburden
- Manage exudate
- Managed with simple inexpensive dressing to keep wound covered
- Enzyme alginogel started to reduce slough and manage exudate

CASE STUDY FOUR — DIABETIC FOOT ULCER

May 2013



June 2013



CASE STUDY FOUR — DIABETIC FOOT ULCER



Feb 2014

For DFU the emphasis is on:

- Radical and repeated debridement
- Bacterial control
- Careful moisture balance to prevent maceration
- Flaminal[®] Forte is suitable for DFU, as it is indicated for moderate to highly exuding wounds

WHY FLAMINAL®?

Offers antimicrobial protection

Minimal risk for resistance development

Debrides and removes necrotic tissue

Self/shared care

Ease of use in small cavities, e.g. perianal abscess/pilonidal sinus/hard-to-reach wounds

No cytotoxicity = safe for skin tissue and protects wound edges

Moist healing environment

Manages exudate

GET IN TOUCH...



Scotland & Ireland

Jonathon Boyne
Regional Business Manager
E: jonathon.boyne@flenhealth.com
M: +447930954063



South West

Adam Page
Regional Business Manager
E: adam.page@flenhealth.com
M: +447930953835



South East

Gerald Twinamasiko
Regional Business Manager
E: gerald.twinamasiko@flenhealth.com
M: +447930953484



The North & Midlands

Lewis Hampshire
Regional Business Manager
E: lewis.hampshire@flenhealth.com
M: +447930953847



Please get in touch to find out more or request a free sample.
Visit our website: <https://www.flenhealth.co.uk/> or email us at info@flenhealth.com

REFERENCES

- Beele H, et al (2012) Expert consensus on a new enzyme alginogel. *Wounds Int* **3(2)**: 42–50
- De Smet K, et al (2009) Pre-clinical evaluation of a new antimicrobial enzyme for the control of wound bioburden. *Wounds* **21(3)**: 65–73
- Flaminal® Hydro instructions for use. Available online: www.flenhealth.co.uk/fileadmin/Products/instruction_leaflets/FlaminalHydro_EN_FR_NL_DE_IT.pdf
- Flaminal® Forte instructions for use. Available online: www.flenhealth.com/fileadmin/Products/instruction_leaflets/FlaminalForte_EN_FR_NL_DE_IT.pdf
- FlenHealth (2021) *Flaminal® Holistic Solution for Wound Management*. Available online: www.flenhealth.co.uk/products/flaminalr-hydro/-/forte/flaminalr-holistic-solution-for-wound-management
- Gottrup F, et al (2013) EWMA document: antimicrobials and non-healing wounds – Evidence, controversies and suggestions. *J Wound Care* **22(5 suppl.)**: S1–S92
- International Wound Infection Institute (2016) *Wound infection in clinical practice*. Wounds International, London
- Jones J, et al (2018) TIME to assess wounds — a clinical evaluation of Flaminal. *Wounds UK* **14(3)**: 63–9
- White R (2014) Flaminal®: a novel approach to the control of wound exudate, bioburden and debridement. *J Tissue Viability* **23(2)**: 78–80



DOWNLOAD CERTIFICATE

WWW.JCN-LIVE.CO.UK/CERTIFICATE